Prognosis of Acute Myelogenous Leukemia

dc.contributor.authorJuan J. Lahuerta-Palacios
dc.contributor.authorSANTIAGO LARREGLA-GARRAUS
dc.contributor.authorFRANCISCO FERNÁNDEZ-DEBORA
dc.contributor.authorRICARDO RUIZ DE ADANA
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:16:02Z
dc.date.available2026-03-22T21:16:02Z
dc.date.issued1982
dc.descriptionCitaciones: 1
dc.description.abstractLetters and Corrections1 July 1982Prognosis of Acute Myelogenous LeukemiaJUAN JOSÉ LAHUERTA-PALACIOS, SANTIAGO LARREGLA-GARRAUS, FRANCISCO FERNÁNDEZ-DEBORA, RICARDO RUIZ DE ADANAJUAN JOSÉ LAHUERTA-PALACIOSSearch for more papers by this author, SANTIAGO LARREGLA-GARRAUSSearch for more papers by this author, FRANCISCO FERNÁNDEZ-DEBORASearch for more papers by this author, RICARDO RUIZ DE ADANASearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-97-1-140_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Barton and Conrad reported in the February 1979 issue (1) an association of elevation of the aspartate transaminase (AST) levels with improved prognosis of acute myelogenous leukemia. Further data confirming this observation are scarce (2-4), although 2 years have elapsed since it was described.We wish to point out a critical defect in the studies that have been carried out: The AST level is considered to be the only factor that influences the prognosis. At the time of diagnosis and during the "induction phase" of acute myelogenous leukemia, there are additional simultaneous prognostic factors: classification, previous or...References1. BARTONCONRAD JM. Beneficial effects of hepatitis in patients with acute myelogenous leukemia. Ann Intern Med. 1979;90:188-90. LinkGoogle Scholar2. BARTONCONRAD JM. Prognostic significance of hepatitis in acute myelogenous leukemia [Abstract]. Clin Res. 1979;27:490A. Google Scholar3. FOONYALECLODFELTERGALE KCKR. Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival. JAMA. 1980;244:1806-7. CrossrefMedlineGoogle Scholar4. JUUAFONT AL. Hepatitis and leukemia [Letter]. Ann Intern Med. 1980;93:780. LinkGoogle Scholar5. SCHUEPBACHSAUTER JC. Inverse correlation of antiviral antibody titers and the remission length in patients treated with viral oncolynate. Cancer. 1981;48:1363-7. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JUAN JOSÉ LAHUERTA-PALACIOS; SANTIAGO LARREGLA-GARRAUS; FRANCISCO FERNÁNDEZ-DEBORA; RICARDO RUIZ DE ADANAAffiliations: Institute Nacional de la Salud Ministerio de Sanidad y Consumo Madrid Spain PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1982Volume 97, Issue 1Page: 140-140KeywordsAcute myeloid leukemiaAminotransferasesSerum glutamic oxaloacetic transaminase ePublished: 1 December 2008 Issue Published: 1 July 1982 PDF downloadLoading ...
dc.identifier.doi10.7326/0003-4819-97-1-140_1
dc.identifier.urihttps://doi.org/10.7326/0003-4819-97-1-140_1
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/86921
dc.language.isoen
dc.publisherAmerican College of Physicians
dc.relation.ispartofAnnals of Internal Medicine
dc.sourceMinisterio de Salud
dc.subjectMedicine
dc.subjectLeukemia
dc.subjectChronic myelogenous leukemia
dc.subjectInternal medicine
dc.subjectAcute leukemia
dc.subjectHepatitis B
dc.subjectImmunology
dc.subjectGastroenterology
dc.subjectOncology
dc.titlePrognosis of Acute Myelogenous Leukemia
dc.typeletter

Files